Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low‐Risk From Intermediate‐ and High‐Risk Prostate Cancer

[1]  H. Carter.  Optimizing Active Surveillance. , 2016, European urology.

[2]  B. Delahunt,et al.  Prostate cancer grading: recent developments and future directions , 2016, BJU international.

[3]  Sarah H. Johnson,et al.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer , 2016, Modern Pathology.

[4]  Sarah H. Johnson,et al.  Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer , 2015, Oncotarget.

[5]  Jiaqiang Wang,et al.  Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma. , 2015, International journal of clinical and experimental medicine.

[6]  H. Cui,et al.  HDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation , 2015, Oncotarget.

[7]  A. Hidalgo-Miranda,et al.  Overexpression of MEOX2 and TWIST1 Is Associated with H3K27me3 Levels and Determines Lung Cancer Chemoresistance and Prognosis , 2014, PloS one.

[8]  A. Folpe,et al.  MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study , 2014, Modern Pathology.

[9]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[10]  J. Brooks,et al.  Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness , 2012, Oncogene.

[11]  J. Lindberg,et al.  Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer , 2012, Oncogene.

[12]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[13]  Peter A Kaufman,et al.  C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Asha A. Nair,et al.  The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. , 2010, Cancer research.

[15]  Ali Amin Al Olama,et al.  Multiple loci on 8q24 associated with prostate cancer susceptibility , 2009, Nature Genetics.

[16]  M. Gleave,et al.  ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. , 2008, Cancer research.

[17]  R. Shah,et al.  Role of the TMPRSS2-ERG gene fusion in prostate cancer. , 2008, Neoplasia.

[18]  W. Catalona,et al.  Pathological features after radical prostatectomy in potential candidates for active monitoring. , 2007, The Journal of urology.

[19]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[20]  Tapio Visakorpi,et al.  Genetic aberrations in prostate cancer by microarray analysis , 2006, International journal of cancer.

[21]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[22]  T. Manabe,et al.  Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities , 2005, The EMBO journal.

[23]  D. Pinkel,et al.  Evaluation of genetic patterns in different tumor areas of intermediate‐grade prostatic adenocarcinomas by high‐resolution genomic array analysis , 2004, Genes, chromosomes & cancer.

[24]  J. Bartlett,et al.  Gene amplifications associated with the development of hormone-resistant prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Cheville,et al.  Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen , 2001 .

[26]  H. Tanke,et al.  Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. , 2001, The American journal of pathology.

[27]  M. Blute,et al.  Pathologic staging of renal cell carcinoma , 2001, Cancer.

[28]  P. Carroll,et al.  Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.